项目来源
台湾省政府科研基金(GRB)
项目主持人
黄建宁
项目受资助机构
台湾省中山医学大学附设医院
项目编号
MOHW104-TDU-B-212-124-005
立项年度
2015
立项时间
未公开
项目级别
省级
研究期限
未知 / 未知
受资助金额
7200.00千元台币
学科
基础医学；临床医学
学科代码
未公开
基金类别
应用研究/补助研究
关键词
口腔癌 ; 总体基因体学 ; 免疫学 ; oral cancer ; metagenomics ; immune repertoire
参与者
未公开
参与机构
未公开
项目标书摘要：由行政院卫生福利部最新公布的民国 101 年死因统计资料显示，口腔癌是国内男性好发癌症第四位，是台湾地区发生率和死亡率增加速度最快之癌症。令人担忧的是，口腔癌是台湾青壮年男性发生最多的癌症，尤其近10年来，其死亡率呈两位数成长，增加了49.1%。口腔癌更是平均死亡年龄最年轻的癌症别，有一半以上患者未满57岁就死亡。由此可见口腔癌已成为严重威胁国人健康的恶性肿瘤。本院连续三年在全国医学中心组别中，口腔癌筛选总数获得国民健康署评选为全国第一名，在癌症品质认证也荣获全国最高等级A级。而本院人体生物资料库也於102年6月16日通过卫生福利部设置核可，人体试验委员会(IRB)亦通过卫生福利部访查合格及国际FERCAP认证。因此，相信本院针对癌症的筛选、预防及检体收集已经有足够的能力。因此，本癌症研究计划针对降低台湾口腔癌发生率与死亡率提出口腔癌早期侦测与诊断计划。多数研究指出口腔癌具有地理空间聚集的现象，且可能与社会经济地位、菸及酒等物质使用有关。我们认为在高流行地区对嚼食槟榔合并抽菸、喝酒习惯的高危险族群进行口腔筛检，并且拟定全面的公共卫生及医疗服务政策是降低癌症口腔癌发生率与死亡率最有效率的方式。因此，本研究议题是分别以基因体规模的总体基因体学以及免疫学和生物资讯学分析，来搜寻口腔癌早期检测和诊断的生物标志。利用本研究团队(中山医学大学附设医院与国立交通大学生物科技学院)已经建立好的 T 细胞受体多样性分析方式，来分析口腔癌治疗前後其患者的血液中的差异性，并与健康对照组比较。此计划还包括透过已知及新颖的口腔癌生物标志，分别建立口腔癌及其癌前病变的新颖诊断晶片；以及寻找和探讨miRNA及其下游基因与癌症的发生机制。尽管近年来医疗技术有长足的进步，但口腔癌的预後却仍未见明显改善，复发机率仍然偏高。我们深切相信透过多团队执行上述的研究议题，一定可以达到降低台湾口腔癌死亡率的最终目的。
Application Abstract: Oral cancer(OC)has been the 4th leading cause of cancer death among males in Taiwan.To date,more than 60%of OC patients are diagnosed as locally advanced cancer stage,which account for poor prognosis.There is an urgent need to develop an effective screening protocol and treatment policy to lower the incidence of OC and to promote these patients’survival.Alcohol,betel nuts and cigarettes have been well-known risk factors of OC.However,there are still many other risk factors such as heavy metal and even virus or bacterial infection.The number of oral cancer screening was rewarded with rank No.1 by the Health Promotion Administration,Ministry of Health and Welfare for consecutive three years among medical centers.The quality of cancer treatment was also verified as the top rank A.The human biobank in our hospital was certified by Ministry of Health and Welfare on June 16,2013.The Institution Review Board was also qualified by Ministry of Health and Welfare,and certified by The Forum for Ethical Review Committees in the Asian and Western Pacific Region.Therefore,we have confidence to be capable of executing cancer translational research.In order to decrease the OC incidence and reduce their mortality,we conduct the programs as follows:High-throughput identification of biomarkers for early detection and diagnosis of OC by integrating metagenomics,immunological approaches and bioinformatics analysis.In this proposal,we will validate known biomarkers for Taiwanese OC patients and intend to identify new biomarkers,which can be microbial communities,the diversity of immune repertoire,and miRNAs by using metagenomics approach,immune repertoire,and bioinformatics analysis.In summary,we will establish interdisciplinary approaches and genome-scale discovery of novel biomarkers for early detection and diagnosis,and develop practical preventive and treatment strategies to reduce mortalities and improve survival,and quality of life of OC in Taiwan.
项目受资助省
台湾省
